Overview

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

Phase:

Phase 1

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Pembrolizumab
Pemetrexed